Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.55 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.55 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157353 | 0.90 | ALDH1A1 (0.66) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL1515846 | 0.90 | ALDH1A1 (0.66) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL6775249 | 0.88 | NPC1 (0.62) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL2645324 | 0.86 | LTA4H (0.58) | ALDH1A1PLOD2CYP3A4MAPTL3MBTL1 | |
| SCHEMBL4102938 | 0.86 | L3MBTL1 (0.68) | CYP3A4KDM4EMAPTL3MBTL1NPC1 | |
| SCHEMBL6101952 | 0.86 | RAB9A (0.66) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL1395223 | 0.86 | RAB9A (0.64) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL1993655 | 0.86 | L3MBTL1 (0.58) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL7433779 | 0.86 | LMNA (0.58) | ALDH1A1KDM4EMAPTL3MBTL1SRD5A2 | |
| SCHEMBL2512740 | 0.86 | RAB9A (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884030-B | Improved labeling of nucleophiles using bipyridines | 安捷伦科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20210333269-A1 | Kits for Using Bispyridines to Improve Labeling of Nucleophiles | AGILENT TECHNOLOGIES, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-11092595-B2 | Use of bispyridines to improve labeling of nucleophiles | AGILENT TECHNOLOGIES, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190041384-A1 | USE OF BISPYRIDINES TO IMPROVE LABELING OF NUCLEOPHILES | PROZYME, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| CN-1681763-A | Chemical compounds | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190041384-A1 | USE OF BISPYRIDINES TO IMPROVE LABELING OF NUCLEOPHILES | PTMS, BTD, DPYD | ALDH1A1 633/4885PLOD2 1699/4885PLOD3 3241/4885 |
| US-11092595-B2 | Use of bispyridines to improve labeling of nucleophiles | PTMS, BTD, DPYD | ALDH1A1 633/4885PLOD2 1699/4885PLOD3 3241/4885 |
| US-20210333269-A1 | Kits for Using Bispyridines to Improve Labeling of Nucleophiles | DPYD, UNG, BTD | ALDH1A1 576/4885PLOD2 1613/4885PLOD3 3022/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | ALDH1A1 1810/4885PLOD2 4746/4885PLOD3 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.